Trial Profile
A retrospective, multicentre,non-randomized, prospective collected data, national study evaluating real-world effectiveness and safety of sofosfuvir/ledipasvir (SOF/LED) and paritaprevir/ritonavir/ombitasvir (2D) with or without ribavirin in patients with GT4 chronic HCV infection.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 03 Feb 2017
Price :
$35
*
At a glance
- Drugs Ledipasvir/sofosbuvir (Primary) ; Ombitasvir/paritaprevir/ritonavir (Primary) ; Ribavirin
- Indications Hepatitis C
- Focus Therapeutic Use
- 03 Feb 2017 New trial record